Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve

Bryan J. Sandler, Roberto Rumbaut, C. Paul Swain, Gustavo Torres, Luis Morales, Lizcelly Gonzales, Sarah Schultz, Mark Talamini, Santiago Horgan

Research output: Contribution to journalArticle

Abstract

Background This report describes the authors' experience with a unique endoluminal, endoscopically delivered and retrieved gastroduodenojejunal bypass sleeve, including short-term weight loss and changes in comorbidities. Methods A prospective, single-center trial was designed. The patients were morbidly obese individuals who met the National Institutes of Health criteria for bariatric surgery. The device used was a unique gastroduodenojejunal bypass sleeve secured at the esophagogastric junction with endoscopic and laparoscopic techniques and designed to create an endoluminal gastroduodenojejunal bypass. At completion of the trial, the device was explanted with endoscopic retrieval. The primary end points were safety and incidence of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in comorbidities, specifically glucose control, use of antihyperglycemic medications, and changes in hemoglobin A1c levels. Results From July 2008 to February 2010, 24 patients were enrolled in the trial. The gastroduodenojejunal bypass sleeve was implanted, left in situ, and then retrieved. The 7 men and 17 women in the study had a mean preoperative body mass index of 42 kg/m 2. The device was successfully delivered in 22 of the 24 patients (92%) and retrieved endoscopically from all 22 patients in whom it was implanted (100%). Two patients were excluded from the study preprocedurally. The one patient was excluded preoperatively due to noncompliance with the preoperative liquid diet. For the other excluded patient, the device was not attempted endoscopically due to significant inflammation at the gastroesophageal junction at the time of laparoscopic evaluation. Of the 22 patients who had the device implanted, 17 maintained it (77%) and completed the full 12-week trial. These patients had 39.7% excess weight loss at completion of the study. The primary reason for early explantation of the device was early postoperative dysphagia. The seven patients with preoperative diabetes mellitus all had normal blood glucose levels throughout the trial, and none required antihyperglycemic medications. All four patients with elevated hemoglobin A1c levels preoperatively showed improvement by the end of the trial. Conclusions This trial demonstrated that the endoluminal gastroduodenojejunal sleeve can achieve excellent weight loss at 12 weeks. No patient safety issues were encountered. Adverse effects were minimal and resolved at endoscopic device removal. Effective glycemic control was demonstrated through use of the device during the trial. Long-term results are needed.

Original languageEnglish (US)
Pages (from-to)3028-3033
Number of pages6
JournalSurgical Endoscopy and Other Interventional Techniques
Volume25
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Equipment and Supplies
Weight Loss
Esophagogastric Junction
Hypoglycemic Agents
Comorbidity
Hemoglobins
Device Removal
Bariatric Surgery
National Institutes of Health (U.S.)
Patient Safety
Deglutition Disorders
Blood Glucose
Diabetes Mellitus
Body Mass Index
Diet
Inflammation
Safety
Glucose
Incidence

Keywords

  • Endoluminal gastroduodenojejunal bypass
  • Gastroduodenojejunal bypass sleeve
  • Morbid obesity

ASJC Scopus subject areas

  • Surgery

Cite this

Sandler, B. J., Rumbaut, R., Swain, C. P., Torres, G., Morales, L., Gonzales, L., ... Horgan, S. (2011). Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surgical Endoscopy and Other Interventional Techniques, 25(9), 3028-3033. https://doi.org/10.1007/s00464-011-1665-6

Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. / Sandler, Bryan J.; Rumbaut, Roberto; Swain, C. Paul; Torres, Gustavo; Morales, Luis; Gonzales, Lizcelly; Schultz, Sarah; Talamini, Mark; Horgan, Santiago.

In: Surgical Endoscopy and Other Interventional Techniques, Vol. 25, No. 9, 09.2011, p. 3028-3033.

Research output: Contribution to journalArticle

Sandler, BJ, Rumbaut, R, Swain, CP, Torres, G, Morales, L, Gonzales, L, Schultz, S, Talamini, M & Horgan, S 2011, 'Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve', Surgical Endoscopy and Other Interventional Techniques, vol. 25, no. 9, pp. 3028-3033. https://doi.org/10.1007/s00464-011-1665-6
Sandler, Bryan J. ; Rumbaut, Roberto ; Swain, C. Paul ; Torres, Gustavo ; Morales, Luis ; Gonzales, Lizcelly ; Schultz, Sarah ; Talamini, Mark ; Horgan, Santiago. / Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. In: Surgical Endoscopy and Other Interventional Techniques. 2011 ; Vol. 25, No. 9. pp. 3028-3033.
@article{f2529a6a549044888c9e7c05e0f718e9,
title = "Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve",
abstract = "Background This report describes the authors' experience with a unique endoluminal, endoscopically delivered and retrieved gastroduodenojejunal bypass sleeve, including short-term weight loss and changes in comorbidities. Methods A prospective, single-center trial was designed. The patients were morbidly obese individuals who met the National Institutes of Health criteria for bariatric surgery. The device used was a unique gastroduodenojejunal bypass sleeve secured at the esophagogastric junction with endoscopic and laparoscopic techniques and designed to create an endoluminal gastroduodenojejunal bypass. At completion of the trial, the device was explanted with endoscopic retrieval. The primary end points were safety and incidence of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in comorbidities, specifically glucose control, use of antihyperglycemic medications, and changes in hemoglobin A1c levels. Results From July 2008 to February 2010, 24 patients were enrolled in the trial. The gastroduodenojejunal bypass sleeve was implanted, left in situ, and then retrieved. The 7 men and 17 women in the study had a mean preoperative body mass index of 42 kg/m 2. The device was successfully delivered in 22 of the 24 patients (92{\%}) and retrieved endoscopically from all 22 patients in whom it was implanted (100{\%}). Two patients were excluded from the study preprocedurally. The one patient was excluded preoperatively due to noncompliance with the preoperative liquid diet. For the other excluded patient, the device was not attempted endoscopically due to significant inflammation at the gastroesophageal junction at the time of laparoscopic evaluation. Of the 22 patients who had the device implanted, 17 maintained it (77{\%}) and completed the full 12-week trial. These patients had 39.7{\%} excess weight loss at completion of the study. The primary reason for early explantation of the device was early postoperative dysphagia. The seven patients with preoperative diabetes mellitus all had normal blood glucose levels throughout the trial, and none required antihyperglycemic medications. All four patients with elevated hemoglobin A1c levels preoperatively showed improvement by the end of the trial. Conclusions This trial demonstrated that the endoluminal gastroduodenojejunal sleeve can achieve excellent weight loss at 12 weeks. No patient safety issues were encountered. Adverse effects were minimal and resolved at endoscopic device removal. Effective glycemic control was demonstrated through use of the device during the trial. Long-term results are needed.",
keywords = "Endoluminal gastroduodenojejunal bypass, Gastroduodenojejunal bypass sleeve, Morbid obesity",
author = "Sandler, {Bryan J.} and Roberto Rumbaut and Swain, {C. Paul} and Gustavo Torres and Luis Morales and Lizcelly Gonzales and Sarah Schultz and Mark Talamini and Santiago Horgan",
year = "2011",
month = "9",
doi = "10.1007/s00464-011-1665-6",
language = "English (US)",
volume = "25",
pages = "3028--3033",
journal = "Surgical Endoscopy",
issn = "0930-2794",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve

AU - Sandler, Bryan J.

AU - Rumbaut, Roberto

AU - Swain, C. Paul

AU - Torres, Gustavo

AU - Morales, Luis

AU - Gonzales, Lizcelly

AU - Schultz, Sarah

AU - Talamini, Mark

AU - Horgan, Santiago

PY - 2011/9

Y1 - 2011/9

N2 - Background This report describes the authors' experience with a unique endoluminal, endoscopically delivered and retrieved gastroduodenojejunal bypass sleeve, including short-term weight loss and changes in comorbidities. Methods A prospective, single-center trial was designed. The patients were morbidly obese individuals who met the National Institutes of Health criteria for bariatric surgery. The device used was a unique gastroduodenojejunal bypass sleeve secured at the esophagogastric junction with endoscopic and laparoscopic techniques and designed to create an endoluminal gastroduodenojejunal bypass. At completion of the trial, the device was explanted with endoscopic retrieval. The primary end points were safety and incidence of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in comorbidities, specifically glucose control, use of antihyperglycemic medications, and changes in hemoglobin A1c levels. Results From July 2008 to February 2010, 24 patients were enrolled in the trial. The gastroduodenojejunal bypass sleeve was implanted, left in situ, and then retrieved. The 7 men and 17 women in the study had a mean preoperative body mass index of 42 kg/m 2. The device was successfully delivered in 22 of the 24 patients (92%) and retrieved endoscopically from all 22 patients in whom it was implanted (100%). Two patients were excluded from the study preprocedurally. The one patient was excluded preoperatively due to noncompliance with the preoperative liquid diet. For the other excluded patient, the device was not attempted endoscopically due to significant inflammation at the gastroesophageal junction at the time of laparoscopic evaluation. Of the 22 patients who had the device implanted, 17 maintained it (77%) and completed the full 12-week trial. These patients had 39.7% excess weight loss at completion of the study. The primary reason for early explantation of the device was early postoperative dysphagia. The seven patients with preoperative diabetes mellitus all had normal blood glucose levels throughout the trial, and none required antihyperglycemic medications. All four patients with elevated hemoglobin A1c levels preoperatively showed improvement by the end of the trial. Conclusions This trial demonstrated that the endoluminal gastroduodenojejunal sleeve can achieve excellent weight loss at 12 weeks. No patient safety issues were encountered. Adverse effects were minimal and resolved at endoscopic device removal. Effective glycemic control was demonstrated through use of the device during the trial. Long-term results are needed.

AB - Background This report describes the authors' experience with a unique endoluminal, endoscopically delivered and retrieved gastroduodenojejunal bypass sleeve, including short-term weight loss and changes in comorbidities. Methods A prospective, single-center trial was designed. The patients were morbidly obese individuals who met the National Institutes of Health criteria for bariatric surgery. The device used was a unique gastroduodenojejunal bypass sleeve secured at the esophagogastric junction with endoscopic and laparoscopic techniques and designed to create an endoluminal gastroduodenojejunal bypass. At completion of the trial, the device was explanted with endoscopic retrieval. The primary end points were safety and incidence of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in comorbidities, specifically glucose control, use of antihyperglycemic medications, and changes in hemoglobin A1c levels. Results From July 2008 to February 2010, 24 patients were enrolled in the trial. The gastroduodenojejunal bypass sleeve was implanted, left in situ, and then retrieved. The 7 men and 17 women in the study had a mean preoperative body mass index of 42 kg/m 2. The device was successfully delivered in 22 of the 24 patients (92%) and retrieved endoscopically from all 22 patients in whom it was implanted (100%). Two patients were excluded from the study preprocedurally. The one patient was excluded preoperatively due to noncompliance with the preoperative liquid diet. For the other excluded patient, the device was not attempted endoscopically due to significant inflammation at the gastroesophageal junction at the time of laparoscopic evaluation. Of the 22 patients who had the device implanted, 17 maintained it (77%) and completed the full 12-week trial. These patients had 39.7% excess weight loss at completion of the study. The primary reason for early explantation of the device was early postoperative dysphagia. The seven patients with preoperative diabetes mellitus all had normal blood glucose levels throughout the trial, and none required antihyperglycemic medications. All four patients with elevated hemoglobin A1c levels preoperatively showed improvement by the end of the trial. Conclusions This trial demonstrated that the endoluminal gastroduodenojejunal sleeve can achieve excellent weight loss at 12 weeks. No patient safety issues were encountered. Adverse effects were minimal and resolved at endoscopic device removal. Effective glycemic control was demonstrated through use of the device during the trial. Long-term results are needed.

KW - Endoluminal gastroduodenojejunal bypass

KW - Gastroduodenojejunal bypass sleeve

KW - Morbid obesity

UR - http://www.scopus.com/inward/record.url?scp=80055095817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055095817&partnerID=8YFLogxK

U2 - 10.1007/s00464-011-1665-6

DO - 10.1007/s00464-011-1665-6

M3 - Article

C2 - 21487876

AN - SCOPUS:80055095817

VL - 25

SP - 3028

EP - 3033

JO - Surgical Endoscopy

JF - Surgical Endoscopy

SN - 0930-2794

IS - 9

ER -